Traders Buy Large Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders acquired 10,911 call options on the stock. This is an increase of approximately 1,740% compared to the typical volume of 593 call options.

Insider Activity

In related news, CEO Lonnel Coats acquired 90,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was purchased at an average price of $1.05 per share, with a total value of $94,500.00. Following the transaction, the chief executive officer now owns 914,359 shares of the company's stock, valued at approximately $960,076.95. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.80% of the company's stock.

Institutional Trading of Lexicon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in LXRX. Raymond James & Associates acquired a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at approximately $25,000. Bank of Montreal Can purchased a new stake in Lexicon Pharmaceuticals in the first quarter valued at approximately $26,000. Baystate Wealth Management LLC purchased a new stake in Lexicon Pharmaceuticals in the second quarter valued at approximately $28,000. TIAA Trust National Association purchased a new stake in Lexicon Pharmaceuticals during the third quarter worth approximately $29,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of Lexicon Pharmaceuticals in the second quarter valued at $33,000.

Lexicon Pharmaceuticals Trading Up 3.4 %

Shares of LXRX traded up $0.06 during midday trading on Wednesday, reaching $1.66. The stock had a trading volume of 4,106,519 shares, compared to its average volume of 2,719,142. Lexicon Pharmaceuticals has a 1-year low of $0.92 and a 1-year high of $3.79. The company's fifty day simple moving average is $1.30 and its two-hundred day simple moving average is $1.44. The company has a debt-to-equity ratio of 0.71, a current ratio of 6.92 and a quick ratio of 6.91.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.01. The company had revenue of $0.16 million for the quarter, compared to the consensus estimate of $1.49 million. Lexicon Pharmaceuticals had a negative net margin of 29,728.25% and a negative return on equity of 118.90%. As a group, research analysts anticipate that Lexicon Pharmaceuticals will post -0.81 EPS for the current year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.